First Trust SMID Growth Strength ETF FSGS
Set alert
As of Nov 2, 1:49 PM ET
- YTD
- +10.25%
- 1 year
- +10.84%
- Open
- 33.19
- Prev close
- 33.04
- Mkt cap
- 29.74M
- Vol
- 47
- Avg vol
- 1.22K
- EPS
- 1.70
- P/E
- 19.48
- Div yield
- 0.00%
More statistics
- Low
- 33.04
- High
- 33.19
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 31.04
- 200-d avg
- 29.14
News
2 weeks ago benzinga.com
What's Going On With Docusign Stock Wednesday?
Docusign (DOCU) stock jumped 2%+, approaching its $75 52-week high despite broader tech declines. Expanded Salesforce deal boosts momentum.
4 weeks ago gurufocus.com
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseasesPR NewswireMELBOURNE, Australia and BASEL,
1 month ago gurufocus.com
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental G
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Paten
3 months ago gurufocus.com
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
5 months ago gurufocus.com
Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion
HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen
5 months ago gurufocus.com
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f